Why FMCG advertising claims get pulled after launch, not before

Kellogg's put "helps support your child's immunity" on Rice Krispies boxes in 2009. The cereal was in US grocery aisles nationwide before that sentence met anyone with enforcement power. In June 2010 the FTC (US Federal Trade Commission) expanded an existing order against the company, one it had obtained the previous year over Frosted Mini-Wheats advertising claiming the cereal improved children's attentiveness by nearly 20%, so that it covered unsubstantiated health claims across Kellogg's foods. On the Mini-Wheats study, the FTC's position was that only about one in seven of the children tested had improved by that much.

Print runs, media flights and retailer promotions were all bought and committed before an outsider tested the evidence. That order of events is the norm in FMCG (fast-moving consumer goods: packaged food, drinks, cosmetics and household products sold in high volume). A claim launches, gets challenged, then gets pulled. The reverse almost never happens, and the reason is structural rather than sloppy.

The pre-clearance myth

Unlike prescription medicines, most FMCG advertising claims are not approved by any regulator before launch. There is no sign-off queue for "70% more moisturising" on a lotion bottle.

The system runs on ex-post enforcement: the advertiser self-certifies that a claim is substantiated, and regulators, competitors, plaintiff lawyers or watchdogs test that assertion afterwards. In the US, the FTC enforces Section 5 of the FTC Act, which bans "unfair or deceptive acts or practices". In the EU, the Unfair Commercial Practices Directive (2005/29/EC) is applied by national consumer authorities. In the UK, the Advertising Standards Authority (ASA) takes tens of thousands of complaints a year and rules under the CAP Code, all of it after publication. In Australia, the ACCC (Australian Competition and Consumer Commission) litigates misleading conduct in the Federal Court.

So the check most marketers picture, a regulator reading copy before print, does not exist for everyday claims. The internal artwork and copy gates that a sibling lesson walks through catch spelling, allergens and legal wording; they do not verify that a study proves what the headline says. The real gatekeeper is the strength of your own evidence file.

Three claim types, three failure patterns

"Clinically proven." The phrase implies controlled trials, adequate sample size, statistical significance, and testing on the finished product rather than one ingredient in isolation. The recurring failure mode is dose drift: the active is tested at a lab concentration well above what survives into the retail formula, and the retail formula inherits the claim. Danone's Activia and DanActive marketing is the reference case. In December 2010 the FTC obtained a consent order barring the company from claiming Activia relieves temporary irregularity or that DanActive prevents colds and flu without FDA (US Food and Drug Administration) approval, alongside a roughly $21 million settlement with 39 state attorneys general. Danone had also withdrawn its Activia and Actimel health claim applications from EFSA (European Food Safety Authority) earlier that year rather than see them rejected.

"Natural." No single legal definition exists in the US or EU for most categories, which makes the word more litigated, not less. US class actions (private suits brought on behalf of a group of consumers) have repeatedly targeted "all natural" on products containing synthetic preservatives or heavily processed ingredients. In the EU, food claims run through the Nutrition and Health Claims Regulation (EC 1924/2006): only claims on the EFSA register may be used, which is why "supports immunity" wording that circulates freely in one market is unusable in another.

"% more effective." Comparative claims mostly attract competitors, not regulators. If Reckitt claimed a laundry treatment removed 50% more stains than the leading brand, the rival would not wait for the FTC: it can file with the National Advertising Division (NAD), the self-regulatory body run by BBB National Programs, or sue under the Lanham Act, which gives competitors standing on false advertising. In the EU, Directive 2006/114/EC requires comparisons to be objective, verifiable and not misleading.

Who actually pulls the claim

Four different actors do the pulling, at four different speeds.

• Competitors move fastest, sometimes within weeks of launch. NAD decisions are not legally binding, but non-compliance gets referred to the FTC, and the industry treats a lost case as a shelf-life sentence on the claim. Most NAD cases end in modified wording rather than withdrawal, which is what a strong file buys you.
• Regulators are slower and carry the penalty power. The ASA cannot fine: its sanctions are the published ruling with your brand named, removal of the ad, and referral to Trading Standards or the CMA. The ACCC goes to court, and the numbers get real. Reckitt's Nurofen Specific Pain range in Australia used the same active ingredient across four variants each targeted at a different pain type and sold at a premium; the Federal Court found the packaging misleading in 2015, and on appeal the penalty rose from A$1.7 million to A$6 million in December 2016. EU authorities can reachreachThe number of unique people exposed to your message in a given period. Unlike impressions, reach counts each person once, no matter how often they see it.View full definition → up to 4% of annual turnover in the member states concerned for widespread infringements under the Omnibus Directive (EU 2019/2161).
• Class action plaintiffs need no regulator at all. Red Bull settled US false advertising claims in 2014 with a fund of around $13 million, paying claimants roughly $10 in cash or $15 in product, while denying any wrongdoing. Note the boundary the case drew: "gives you wings" reads as puffery, but the surrounding energy, concentration and reaction-time messaging is measurable, and measurable is actionable.
• Watchdogs and NGOs hold no legal power and set the media cycle anyway. Truth in Advertising (TINA.org) in the US and BEUC at EU level both feed complaints to regulators.

A claim can clear internal legal review and still die, because legal modelled regulatory risk while nobody modelled the competitor whose brand manager has just lost two facings and has outside counsel on retainer.

What a substantiation file actually needs

Substantiation is the evidence you hold at the moment the claim is published, not evidence you assemble once challenged. Every forum above asks the same question: what did you have, and when. The US formulation is "competent and reliable scientific evidence"; EU and UK frameworks phrase it differently and test the same thing.

A defensible file contains:

1. Study design: sample size, control group, significance, run on the marketed formula and dose rather than a proxy.
2. Claim-to-evidence mapping: the ad wording must match what was measured. "Reduces wrinkles" and "reduces the appearance of wrinkles" are different claims needing different proof.
3. Comparative baseline documentation: for a "% more" claim, head-to-head testing against the competitor's current formulation, not last year's or their own marketing.
4. Category sign-off: EFSA register verification for EU food and health claims; for cosmetics, the EU Cosmetic Products Regulation (EC 1223/2009), which bans claims implying medicinal effects.
5. Version control and an expiry date: substantiation decays. A supplier swap, a cost-down reformulation or a competitor reformulating their product can falsify a claim without a single word of copy changing.

Build the file as if a rival's outside counsel will read it in six months, because that is the realistic case.

When the claim gets pulled: what it actually costs

The withdrawal itself is rarely the expensive part. The costs sit downstream.

Artwork has to be re-originated and re-approved, and printed film and laminate for the old version becomes scrap. Stock already in the retailer's depot either gets stickered, which most grocers charge you for, or returned. Media committed for the quarter is written off against a message you can no longer run. Then the second-order problem: the claim was usually the reason the retailer took the listing. Pull it and the range review argument thins out, so the SKU competes on price at the next negotiation.

Two failure modes are worth naming. The first is claim contagion: an FTC order, as Kellogg's found, can be written to cover a whole portfolio, not just the product that triggered it, which means every future claim across the range needs pre-approval that competitors do not need. The second is asymmetric geography. A claim substantiated for the US can be unusable in the EU because it is absent from the EFSA register, and a team that builds one global file discovers the gap after the pan-European launch, not before.

The FTC's guidance on health claims substantiation is a useful public reference even for teams working mainly in Europe, since the evidentiary logic carries across.

🎬 [VIDEO: "How the FTC Regulates Advertising" - https://www.youtube.com/results?search_query=how+the+ftc+regulates+advertising - search for FTC or law-school explainer videos covering Section 5 enforcement and substantiation standards, useful for a plain-language walkthrough of the ex-post enforcement model]

Key Takeaways

• FMCG claims are almost never pre-cleared; enforcement is after the fact, so the safeguard is the evidence file you hold on the day of publication, not a government stamp.
• "Clinically proven", "natural" and comparative "% more" claims fail in different ways: dose drift between the tested and shipped formula, terms with no legal definition, and comparators that have moved.
• Competitors and class action plaintiffs often act faster than regulators, via NAD, the Lanham Act or a consumer suit, because their commercial motive is direct.
• Penalties range from an ASA ruling with your brand named to A$6 million against Reckitt in Australia and up to 4% of turnover under the EU Omnibus Directive.
• The real cost of a pulled claim is downstream: scrapped artwork and packaging, wasted media, retailer chargebacks, portfolio-wide orders, and a listing that now has to be defended on price.